Tumor angiogenesis is a classic hallmark of cancer and in vitro and in vivo studies focused on elucidating the mechanisms of tumor vascularization have led to the development of anti-angiogenic drugs targeting VEGF signaling pathways such as: bevacizumab, axitinib, and sunitinib4,12. The gene discussed is VEGFA; the disease is neoplasm.